NCT05105880 is a clinical trial in Congenital Heart Disease, sponsored by Women and Children's Hospital of Linyi City.

Who is sponsoring NCT05105880?

NCT05105880 is sponsored by Women and Children's Hospital of Linyi City.

What condition does NCT05105880 study?

NCT05105880 studies Congenital Heart Disease.

Is NCT05105880 still recruiting?

NCT05105880 is currently completed. Last updated 8 November 2021.

Last reviewed 2021-11-08 · How we verify

NCT05105880

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Auscultation and Pulse Oximetry Combined Screening of Neonatal Congenital Heart Disease

Completed Last updated 8 November 2021

What this trial tests

trial in Congenital Heart Disease in 40,000 participants. Completed in 1 July 2020.

Timeline

1 January 2018

Primary endpoint
31 December 2019

1 July 2020

Quick facts

Lead sponsor	Women and Children's Hospital of Linyi City
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40,000
Start date	1 January 2018
Primary completion	31 December 2019
Estimated completion	1 July 2020
Sites	1 location across China

Conditions studied

Congenital Heart Disease — all drugs for Congenital Heart Disease →

Sponsor

Women and Children's Hospital of Linyi City

Who can join

Adults 0 Hours to 72 Hours, any sex, with Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators conducted this retrospective study in a large single center with an annual birth of more than 20,000 newborns, from January 1, 2018 to December 31, 2019, to confirm the applicability and accuracy of pulse oximetry (POX) combined cardio-auscultation to screen congenital heart disease for neonates.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Large scale application of pulse oximeter and auscultation in screening of neonatal congenital heart disease.
Huang Y, Zhong S, Zhang X, Kong L, et al · · 2022 · cited 13× · PMID 35962379 · DOI 10.1186/s12887-022-03540-7

Verify or expand the search:

Other recruiting trials for Congenital Heart Disease

Currently open trials in the same condition.

NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
NCT07023367 — Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents · NA · recruiting
NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05105880 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women and Children's Hospital of Linyi City
Last refreshed: 8 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05105880.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing